Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance) Meeting Abstract

  


Authors: Abou-Alfa, G. K.; Niedzwieski, D.; Knox, J. J.; Kaubisch, A.; Posey, J.; Tan, B. R.; Kavan, P.; Goel, R.; Lammers, P. E.; Bekaii-Saab, T. S.; Tam, V. C.; Rajdev, L.; Kelley, R. K.; Siegel, A. B.; Balletti, J.; Harding, J. J.; Schwartz, L. H.; Goldberg, R. M.; Bertagnolli, M. M.; Venook, A. P.
Abstract Title: Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance)
Meeting Title: 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 34
Issue: 15 Suppl.
Meeting Dates: 2016 Jun 3-7
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2016-05-20
Start Page: 206s
Language: English
ACCESSION: WOS:000404665405231
DOI: 10.1200/JCO.2016.34.15_suppl.4003
PROVIDER: wos
Notes: Meeting Abstract: 4003 -- Source: Wos
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. James Joseph Harding
    250 Harding
  2. Ghassan Abou-Alfa
    568 Abou-Alfa
  3. Jennifer Balletti
    3 Balletti
Related MSK Work